

Jai Radhakrishnan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8692520/publications.pdf>

Version: 2024-02-01

197
papers

13,757
citations

25034

57
h-index

23533

111
g-index

221
all docs

221
docs citations

221
times ranked

14014
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathologic Classification of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2010, 21, 556-563.	6.1	1,191
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	5.2	782
3	Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature, 2012, 482, 98-102.	27.8	560
4	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	13.7	526
5	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 142-151.	27.0	456
6	Acute Phosphate Nephropathy following Oral Sodium Phosphate Bowel Purgative. Journal of the American Society of Nephrology: JASN, 2005, 16, 3389-3396.	6.1	358
7	Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney International, 2003, 64, 281-289.	5.2	333
8	The KDIGO practice guideline on glomerulonephritis: reading between the (guide)linesâ€”application to the individual patient. Kidney International, 2012, 82, 840-856.	5.2	332
9	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, 753-779.	5.2	325
10	Lithium Nephrotoxicity. Journal of the American Society of Nephrology: JASN, 2000, 11, 1439-1448.	6.1	306
11	Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 748-756.	4.5	295
12	Presentation and Outcomes of Patients with ESKD and COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1409-1415.	6.1	270
13	Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney International, 2010, 78, 1171-1177.	5.2	257
14	Postmortem Kidney Pathology Findings in Patients with COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 2158-2167.	6.1	241
15	Donor-Specific Antibodies Adversely Affect Kidney Allograft Outcomes. Journal of the American Society of Nephrology: JASN, 2012, 23, 2061-2071.	6.1	234
16	The Modern Spectrum of Renal Biopsy Findings in Patients with Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1718-1724.	4.5	227
17	Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International, 2017, 92, 37-46.	5.2	220
18	Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN. Journal of the American Society of Nephrology: JASN, 2016, 27, 1278-1287.	6.1	210

#	ARTICLE	IF	CITATIONS
19	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
20	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	13.7	197
21	Bacterial infectionâ€related glomerulonephritis in adults. Kidney International, 2013, 83, 792-803.	5.2	196
22	Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrology Dialysis Transplantation, 2005, 20, 2139-2145.	0.7	195
23	Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis. Kidney International Reports, 2020, 5, 1149-1160.	0.8	184
24	Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1676-1683.	4.5	180
25	Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrology Dialysis Transplantation, 2003, 18, 2039-2046.	0.7	172
26	Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney International, 2010, 77, 152-160.	5.2	167
27	A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney International, 2017, 91, 787-789.	5.2	161
28	Whole-Exome Sequencing in Adults With Chronic Kidney Disease. Annals of Internal Medicine, 2018, 168, 100.	3.9	154
29	Urinary Neutrophil Gelatinase-Associated Lipocalin Predicts Mortality and Identifies Acute Kidney Injury in Cirrhosis. Digestive Diseases and Sciences, 2012, 57, 2362-2370.	2.3	145
30	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 281-295.	5.2	135
31	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology: JASN, 2018, 29, 2745-2754.	6.1	128
32	Renal Biopsy in the Very Elderly. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1073-1082.	4.5	124
33	C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney International, 2018, 93, 977-985.	5.2	123
34	The Treatment of Minimal Change Disease in Adults. Journal of the American Society of Nephrology: JASN, 2013, 24, 702-711.	6.1	116
35	Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney International, 2013, 84, 34-44.	5.2	106
36	Use of mycophenolate mofetil in resistant membranous nephropathy. American Journal of Kidney Diseases, 2000, 36, 250-256.	1.9	105

#	ARTICLE	IF	CITATIONS
37	The pathophysiology of edema formation in the nephrotic syndrome. <i>Kidney International</i> , 2012, 82, 635-642.	5.2	102
38	Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study. <i>Diabetes Care</i> , 2003, 26, 1402-1407.	8.6	99
39	Awareness of kidney disease in the US population: Findings from the National Health and Nutrition Examination Survey (NHANES) 1999 to 2000. <i>American Journal of Kidney Diseases</i> , 2004, 44, 185-197.	1.9	99
40	Mycophenolate Mofetil for the Treatment of Interstitial Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 718-722.	4.5	95
41	Rationale and design of the Kidney Precision Medicine Project. <i>Kidney International</i> , 2021, 99, 498-510.	5.2	94
42	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. <i>Kidney International Reports</i> , 2017, 2, 800-810.	0.8	89
43	Treatment of Idiopathic FSGS with Adrenocorticotrophic Hormone Gel. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2072-2081.	4.5	86
44	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. <i>Kidney International</i> , 2014, 86, 246-250.	5.2	84
45	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH) gel. <i>Drug Design, Development and Therapy</i> , 2011, 5, 147.	4.3	83
46	Treatment of Resistant Glomerular Diseases with Adrenocorticotrophic Hormone Gel: A Prospective Trial. <i>American Journal of Nephrology</i> , 2012, 36, 58-67.	3.1	83
47	The relevance of congestion in the cardio-renal syndrome. <i>Kidney International</i> , 2013, 83, 384-391.	5.2	80
48	Association Between Declined Offers of Deceased Donor Kidney Allograft and Outcomes in Kidney Transplant Candidates. <i>JAMA Network Open</i> , 2019, 2, e1910312.	5.9	78
49	ANCA-associated glomerulonephritis in the very elderly. <i>Kidney International</i> , 2011, 79, 757-764.	5.2	77
50	Drug-Induced Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1300-1310.	4.5	75
51	Cardiac Transplantation Using Extended-Donor Criteria Organs for Systemic Amyloidosis Complicated by Heart Failure. <i>Transplantation</i> , 2007, 83, 539-545.	1.0	73
52	Race/Ethnicity, Poverty Status, and Renal Transplant Outcomes. <i>Transplantation</i> , 2005, 80, 917-924.	1.0	71
53	Angiotensin converting enzyme inhibition in chronic allograft nephropathy. <i>Transplantation</i> , 2002, 73, 783-788.	1.0	70
54	Gastrointestinal disorders and renal failure: exploring the connection. <i>Nature Reviews Nephrology</i> , 2010, 6, 480-492.	9.6	68

#	ARTICLE	IF	CITATIONS
55	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
56	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
57	Genomic Mismatch at <i>LIMS1</i> Locus and Kidney Allograft Rejection. New England Journal of Medicine, 2019, 380, 1918-1928.	27.0	63
58	Use of Mycophenolate Mofetil in Autoimmune and Renal Diseases. Transplantation, 2005, 80, S265-S271.	1.0	62
59	Advances in the Treatment of Lupus Nephritis. Annual Review of Medicine, 2001, 52, 63-78.	12.2	57
60	Procurement Biopsies in the Evaluation of Deceased Donor Kidneys. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1876-1885.	4.5	57
61	Renal Transplantation in Anticardiolipin Antibody-Positive Lupus Erythematosus Patients. American Journal of Kidney Diseases, 1994, 23, 286-289.	1.9	56
62	De novo thrombotic microangiopathy following treatment with sirolimus: report of two cases. Nephrology Dialysis Transplantation, 2005, 20, 203-209.	0.7	50
63	Renal-limited 'lupus-like' nephritis. Nephrology Dialysis Transplantation, 2012, 27, 2337-2342.	0.7	50
64	IgA Nephropathy with Minimal Change Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1033-1039.	4.5	49
65	Rituximab treatment for fibrillary glomerulonephritis. Nephrology Dialysis Transplantation, 2014, 29, 1925-1931.	0.7	47
66	High rate of renal recovery in survivors of COVID-19 associated acute renal failure requiring renal replacement therapy. PLoS ONE, 2020, 15, e0244131.	2.5	46
67	Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Seminars in Nephrology, 2003, 23, 406-411.	1.6	42
68	Early experience with COVID-19 in kidney transplantation. Kidney International, 2020, 97, 1074-1075.	5.2	41
69	The Role of Kidney Biopsy in Heart Transplant Candidates With Kidney Disease. Transplantation, 2010, 89, 887-893.	1.0	40
70	Antiphospholipid antibody syndrome and renal disease. Current Opinion in Nephrology and Hypertension, 2001, 10, 175-181.	2.0	39
71	Under-documentation of chronic kidney disease in the electronic health record in outpatients. Journal of the American Medical Informatics Association: JAMIA, 2010, 17, 588-594.	4.4	39
72	Drug-Induced Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1287-1290.	4.5	39

#	ARTICLE	IF	CITATIONS
73	Association between Reperfusion Renal Allograft Biopsy Findings and Transplant Outcomes. Journal of the American Society of Nephrology: JASN, 2017, 28, 3109-3117.	6.1	39
74	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
75	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
76	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38
77	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. Autoimmunity Reviews, 2020, 19, 102671.	5.8	37
78	Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney International, 2010, 78, 337-342.	5.2	36
79	Glomerular Diseases Associated With Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Advances in Chronic Kidney Disease, 2014, 21, 48-55.	1.4	36
80	Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis ofÂdeÂnovo collapsing glomerulopathy in renalÂallografts. Kidney International, 2018, 94, 1189-1198.	5.2	36
81	Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. Journal of the American Society of Hypertension, 2012, 6, 338-345.	2.3	35
82	CYCLOSPORINE TREATMENT OF GLOMERULAR DISEASES. Annual Review of Medicine, 1999, 50, 1-15.	12.2	31
83	Idiopathic Membranous Nephropathy: Clinical and Histologic Prognostic Features and Treatment Patterns over Time at a Tertiary Referral Center. American Journal of Nephrology, 2012, 36, 78-89.	3.1	31
84	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovascular Interventions, 2022, 15, 753-766.	2.9	31
85	Thrombotic microangiopathies. Critical Care Clinics, 2002, 18, 309-320.	2.6	30
86	Importance of stratifying acute kidney injury in cardiogenic shock resuscitated with mechanical circulatory support therapy. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 856-864.e4.	0.8	30
87	The Epidemiology of Peritonitis in Acute Peritoneal Dialysis: A Comparison Between Open- and Closed-Drainage Systems. American Journal of Kidney Diseases, 1993, 21, 300-309.	1.9	29
88	Pilot Study of Return of Genetic Results to Patients in Adult Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 651-664.	4.5	28
89	Towards the Incidence of Acute Phosphate Nephropathy. Journal of the American Society of Nephrology: JASN, 2007, 18, 3020-3022.	6.1	26
90	Trimethoprim-Associated Hyponatremia. American Journal of Kidney Diseases, 2013, 62, 1188-1192.	1.9	26

#	ARTICLE	IF	CITATIONS
91	Is Newer Safer? Adverse Events Associated with First-Line Therapies for ANCA-Associated Vasculitis and Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1657-1667.	4.5	26
92	Lupus Nephritis: Treatment of Resistant Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 154-161.	4.5	24
93	One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 115-116.	3.0	24
94	How COVID-19 Has Changed the Management of Glomerular Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 876-879.	4.5	23
95	Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device. Circulation: Heart Failure, 2020, 13, e006326.	3.9	22
96	Treatment of nephrotic syndrome with adrenocorticotrophic hormone (ACTH). Discovery Medicine, 2011, 12, 91-6.	0.5	22
97	The Evidence-Based Approach to Adult-Onset Idiopathic Nephrotic Syndrome. Frontiers in Pediatrics, 2015, 3, 78.	1.9	21
98	Monoclonal IgG1 κ Anti- α 1-antitrypsin Glomerular Basement Membrane Disease: A Case Report. American Journal of Kidney Diseases, 2015, 65, 322-326.	1.9	21
99	Association of HLA Typing and Alloimmunity With Posttransplantation Membranous Nephropathy: A Multicenter Case Series. American Journal of Kidney Diseases, 2020, 76, 374-383.	1.9	21
100	Standardized Outcomes in Nephrology- α Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
101	Radiographic Periodontal Bone Loss in Chronic Kidney Disease. Journal of Periodontology, 2012, 83, 602-611.	3.4	19
102	Racial and socioeconomic factors in glomerular disease. Seminars in Nephrology, 2001, 21, 403-410.	1.6	19
103	Echocardiographic changes following hemodialysis initiation in patients with advanced chronic kidney disease and symptomatic heart failure with reduced ejection fraction. Clinical Nephrology, 2012, 77, 366-375.	0.7	18
104	The Treatment of Idiopathic Focal Segmental Glomerulosclerosis in Adults. Advances in Chronic Kidney Disease, 2014, 21, 434-441.	1.4	18
105	Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Blood, 2015, 126, 188-188.	1.4	18
106	Transjugular Intrahepatic Portosystemic Shunts in Hemodialysis-dependent Patients and Patients with Advanced Renal Insufficiency: Safety, Caution, and Encephalopathy. Journal of Vascular and Interventional Radiology, 2008, 19, 516-520.	0.5	17
107	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
108	The Evolving Role of Calcineurin Inhibitors in Treating Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1066-1072.	4.5	17

#	ARTICLE	IF	CITATIONS
109	Anti-neutrophil cytoplasmic antibody associated glomerulonephritis complicating treatment with hydralazine. <i>Kidney International</i> , 2021, 100, 440-446.	5.2	17
110	Concurrent Anti-“Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series. <i>American Journal of Kidney Diseases</i> , 2021, 78, 219-225.e1.	1.9	16
111	Rituximab Treatment of Dysproteinemias Affecting the Kidney: A Review of Three Cases. <i>American Journal of Kidney Diseases</i> , 2007, 50, 641-644.	1.9	15
112	Renal Transplantation in Familial Dysautonomia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1676-1680.	4.5	15
113	The changing pattern of glomerular disease in HIV and Hepatitis C co-infected patients in the era of HAART. <i>Clinical Nephrology</i> , 2013, 79, 285-291.	0.7	15
114	A rare infectious cause of renal allograft dysfunction. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1103-1107.	1.9	14
115	Worth a Second Look. <i>American Journal of Medicine</i> , 2009, 122, 24-26.	1.5	14
116	Live Donor Renal Anatomic Asymmetry and Posttransplant Renal Function. <i>Transplantation</i> , 2015, 99, e66-e74.	1.0	14
117	A Newly Recognized Endemic Region of CKD of Undetermined Etiology (CKDu) in South India-“Tondaimandalam Nephropathy”. <i>Kidney International Reports</i> , 2020, 5, 2066-2073.	0.8	14
118	An overlapping etiology of rapidly progressive glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2004, 43, 388-393.	1.9	13
119	A 56-year-old woman with sarcoidosis and acute renal failure. <i>Kidney International</i> , 2008, 74, 817-821.	5.2	13
120	Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?. <i>Kidney International</i> , 2012, 82, 1256-1260.	5.2	13
121	Mineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?. <i>Heart Failure Reviews</i> , 2015, 20, 283-290.	3.9	13
122	Predictors of outcome for severe IgA Nephropathy in a multi-ethnic U.S. cohort. <i>Clinical Nephrology</i> , 2015, 84 (2015), 145-155.	0.7	13
123	Cyclosporin treatment of glomerular diseases. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1053-1063.	4.1	12
124	Cryofibrinogen-Associated Glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 302-308.	1.9	12
125	Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 643-643.	1.4	12
126	Case 5-2010. <i>New England Journal of Medicine</i> , 2010, 362, 636-646.	27.0	11

#	ARTICLE	IF	CITATIONS
127	Proteinuria as a surrogate marker for renal outcome: are we there yet?. <i>Kidney International</i> , 2015, 88, 1228-1230.	5.2	11
128	Persistent Hepatitis C Virus~Associated Cryoglobulinemic Glomerulonephritis in~Patients Successfully Treated With~Direct-Acting Antiviral Therapy. <i>Kidney International Reports</i> , 2018, 3, 985-990.	0.8	11
129	Capillary leak syndrome: a cytokine and catecholamine storm?. <i>Kidney International</i> , 2019, 95, 1009-1011.	5.2	10
130	Fludarabine treatment of cryoglobulinemic glomerulonephritis. <i>American Journal of Kidney Diseases</i> , 2002, 40, 644-648.	1.9	9
131	Pharmacological Effects of Ex~Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation. <i>Stem Cells Translational Medicine</i> , 2021, 10, 1588-1601.	3.3	9
132	Clinical Predictors and Prognosis of Recurrent IgA Nephropathy in the Kidney Allograft. <i>Glomerular Diseases</i> , 2022, 2, 42-53.	1.0	9
133	Do meta-analyses in nephrology change the way we treat patients?. <i>Kidney International</i> , 2010, 78, 1080-1087.	5.2	8
134	Impact of the National Institutes of Health Focal Segmental Glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGS. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 527-534.	0.7	8
135	In-Hospital Survival and Neurological Recovery Among Patients Requiring Renal Replacement Therapy in Post~Cardiac Arrest Period. <i>Kidney International Reports</i> , 2019, 4, 674-678.	0.8	8
136	Venous Thromboembolism and Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 3-4.	4.5	7
137	Dashboards to Facilitate Nephrology Disaster Planning in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1298-1302.	0.8	7
138	Optimizing Kidney Replacement Therapy During the COVID-19 Pandemic Across a Complex Healthcare System. <i>Frontiers in Medicine</i> , 2020, 7, 604182.	2.6	7
139	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	5.2	7
140	Evaluation of a computer program for teaching laboratory diagnosis of acid-base disorders. <i>Journal of Biomedical Informatics</i> , 1992, 25, 562-568.	0.7	6
141	Nephrological and obstetric complications of the antiphospholipid syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 819-829.	4.1	6
142	A pharmacist~physician collaborative care model in chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2021, 23, 2026-2029.	2.0	6
143	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. <i>Kidney Medicine</i> , 2022, 4, 100457.	2.0	6
144	Temporal Changes in Post-Infectious Glomerulonephritis in Japan (1976-2009). <i>PLoS ONE</i> , 2016, 11, e0157356.	2.5	5

#	ARTICLE	IF	CITATIONS
145	Anticomplement therapies in “secondary thrombotic microangiopathies” ready for prime time?. <i>Kidney International</i> , 2019, 96, 833-835.	5.2	5
146	Ultra-low-contrast angiography in patients with advanced chronic kidney disease and previous coronary artery bypass surgery. <i>Coronary Artery Disease</i> , 2019, 30, 346-351.	0.7	5
147	Patient perspectives and involvement in precision medicine research. <i>Kidney International</i> , 2021, 99, 511-514.	5.2	5
148	Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. <i>ASAIO Journal</i> , 2021, 67, 1087-1096.	1.6	5
149	Citius, altius, fortius . . . faster, higher, stronger. <i>Kidney International</i> , 2019, 95, 476-478.	5.2	4
150	Pathogenesis of SLE Nephritis in the Era of Precision Medicine. <i>Current Rheumatology Reviews</i> , 2018, 14, 140-144.	0.8	4
151	Treating lupus in the kidney: where are we now, and where are we going?. <i>Discovery Medicine</i> , 2011, 12, 341-9.	0.5	4
152	A Core Outcome Set for Trials in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 53-64.	4.5	4
153	The Case of Renal failure after percutaneous closure of a perivalvular leak. <i>Kidney International</i> , 2008, 74, 539-540.	5.2	3
154	Risk factors for chronic kidney disease following acute kidney injury in pediatric allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1665-1673.	2.4	3
155	Hemoglobinuric acute kidney injury from aortic root graft malfunction. <i>Clinical Nephrology</i> , 2014, 82, 221-4.	0.7	3
156	A challenge to the kidney community by a man-made crisis. <i>Kidney International</i> , 2022, 101, 854-855.	5.2	3
157	The burden of prescription coverage of kidney failure patients in the United States: is Medicare Part D the answer?. <i>Kidney International</i> , 2006, 69, 1099-1100.	5.2	2
158	The Authors Reply:. <i>Kidney International</i> , 2014, 85, 214.	5.2	2
159	Native Valve Emphysematous Endocarditis Caused by <i>Fingoldia magna</i> in a Novel Pathogenic Role. <i>Infectious Diseases in Clinical Practice</i> , 2016, 24, 57-59.	0.3	2
160	TCT-32 Clinical Outcomes of Imaging- and Physiology-Guided PCI Without Contrast Administration in Advanced Renal Failure. <i>Journal of the American College of Cardiology</i> , 2019, 74, B32.	2.8	2
161	Reversal of Donor Hepatitis C Virus-Related Mesangial Proliferative GN in a Kidney Transplant Recipient. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2246-2249.	6.1	2
162	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. <i>Kidney International Reports</i> , 2020, 5, 860-871.	0.8	2

#	ARTICLE	IF	CITATIONS
163	The Case Euglycemic ketoacidosis in a patient on continuous renal replacement therapy. Kidney International, 2021, 99, 1507-1508.	5.2	2
164	A focus group study of self-management in patients with glomerular disease.. Kidney International Reports, 2021, 7, 56-67.	0.8	2
165	Strategies for Renal Protection in Cardiovascular Interventions. Korean Circulation Journal, 2022, 52, 485.	1.9	2
166	A case of nephrocalcinosis. Kidney International, 2009, 75, 856-859.	5.2	1
167	Lupus Nephritis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 136-137.	4.5	1
168	KI Reports and World Kidney Day. Kidney International Reports, 2017, 2, 125-126.	0.8	1
169	Kidney International Reports : The First Year. Kidney International Reports, 2017, 2, 503.	0.8	1
170	KI Reports in 2019: Further Expanding Access to Research in Nephrology. Kidney International Reports, 2019, 4, 1-2.	0.8	1
171	Kidney International Reports: Three Years of Publication. Kidney International Reports, 2020, 5, 117.	0.8	1
172	Kidney International and the COVID-19 infection. Kidney International, 2020, 97, 823.	5.2	1
173	Milestones in nephrology and welcoming the future: the 61st anniversary of the International Society of Nephrology. Kidney International, 2021, 99, 2-4.	5.2	1
174	Reflections and Next Stages for Kidney International Reports. Kidney International Reports, 2021, 6, 1-2.	0.8	1
175	Looking back and moving forward. Kidney International, 2021, 99, 787-790.	5.2	1
176	Successful Use of Arteriovenous Graft for Hemodialysis Access After Left Ventricular Assist Device Placement. Kidney Medicine, 2021, 3, 1091-1094.	2.0	1
177	Impact of bone marrow minimal residual disease status on quality of organ response in systemic <sc>AL</sc> amyloidosis. American Journal of Hematology, 2022, 97, .	4.1	1
178	International Physicians Delphi Survey: Managing Patients With IgA Nephropathy. Kidney International Reports, 2022, 7, 2076-2080.	0.8	1
179	Polycystic liver disease treated with therapeutic excision. Kidney International, 2009, 76, 803.	5.2	0
180	Back-bench split of a deceased-donor horseshoe kidney for two transplant recipients. Kidney International, 2009, 76, 1012.	5.2	0

#	ARTICLE	IF	CITATIONS
181	The Authors Reply:. Kidney International, 2013, 83, 969.	5.2	0
182	The Evolution of Treating Glomerular Diseases: Letting Science Lead the Way. Advances in Chronic Kidney Disease, 2014, 21, 119-120.	1.4	0
183	The Author Replies:. Kidney International, 2015, 87, 664.	5.2	0
184	Good news and best wishes for 2016 to the global nephrology community from Kidney International. Kidney International, 2016, 89, 2.	5.2	0
185	The Launch of Kidney International Reports. Kidney International Reports, 2016, 1, 1-2.	0.8	0
186	A 31-Year-Old Man With a Ring-Enhancing Brain Lesion. Journal of Neuro-Ophthalmology, 2017, 37, 172-175.	0.8	0
187	Kidney International Reports: Two Years of Publication. Kidney International Reports, 2018, 3, 509.	0.8	0
188	Intensive BP control and incident kidney disease: what can we learn fromÂurinaryÂbiomarkers?. Kidney International, 2019, 95, 1007-1009.	5.2	0
189	The Case A hidden deposit. Kidney International, 2020, 97, 815-816.	5.2	0
190	Treatment of glomerular diseases: pioneering clinical trials. Kidney International, 2020, 97, 433-436.	5.2	0
191	Late Relapses of Membranous Nephropathy: A Case Series. Kidney360, 2021, 2, 974-982.	2.1	0
192	Five Years (and Counting) of Expanding Access to Kidney Disease Research. Kidney International Reports, 2021, 6, 1487-1488.	0.8	0
193	Treatment of Non-Amyloid Monoclonal Gammopathies of Renal Significance (MGRS) with Clone Directed Therapies-Single Center Experience. Blood, 2019, 134, 5565-5565.	1.4	0
194	ANCA Vasculitis Treatment in the Dialysis Patient. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1617-1619.	4.5	0
195	Low glomerular filtration rate in apparently healthy young individuals is an important factor preventing kidney transplantation from living kidney donors â€“ A single-center observational study from India. Indian Journal of Transplantation, 2021, 15, 325.	0.1	0
196	Six Years of KI Reports: Milestones Behind and Ahead. Kidney International Reports, 2022, 7, 1-2.	0.8	0
197	Diagnosis and Treatment of Patients With FSGS/SRNS: A Delphi Survey. Kidney International Reports, 2022, , .	0.8	0